Crossmark

Pharmacophore based discovery of dual inhibitors targeting TOP1 and TOP2A in resistant triple negative breast cancer

Crossref DOI link: https://doi.org/10.1007/s44371-026-00603-x

Published Online: 2026-04-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Onaji, Enayi https://orcid.org/0009-0001-4600-6876
Adaji, Grace https://orcid.org/0009-0000-3966-0848
Azubuike, Chukwunenye Christopher https://orcid.org/0009-0008-7233-898X
Adam, Mukhtar Sani https://orcid.org/0009-0006-0775-048X
Junior, Apeh Lucky https://orcid.org/0009-0003-0160-878X
Jimoh, Yusuf https://orcid.org/0000-0001-9853-0314
Ojila, Edwin Ameh https://orcid.org/0009-0001-0296-0502
License Information

Text and Data Mining valid from 2026-04-22

Version of Record valid from 2026-04-22
More Information

Article History

Received: 1 July 2025

Accepted: 16 March 2026

First Online: 22 April 2026

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.